Congestive heart failure in older women treated with adjuvant anthracycline chemotherapy for breast cancer.

By M. Pinder, Z. Duan, J. Goodwin, G. Hortobagyi, S. Giordano. Journal of Clinical Oncology, 2007

597 citations recorded by the source corpus.

Subfields: Cancer Research, Cardiology and Cardiovascular Medicine, Oncology

View Paper: https://www.semanticscholar.org/paper/3ec884deef8e146f0a047d6e6750490aceea8a16

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Cardiology and Cardiovascular Medicine

Citations in the corpus

Cardiotoxicity of anticancer treatments: Epidemiology, detection, and management (2016, methodology): “2-fold higher rate of cardiac death compared with the age-matched and sex-matched national average.(18,19) Compared with controls, long-term childhood cancer survivors had 15-fold increased rates of congestive HF, 10-fold higher rates of CVD, and 9-fold higher rates of stroke.”
Expert consensus for multimodality imaging evaluation of adult patients during and after cancer therapy: a report from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. (2014, background): “As mentioned with echocardiography, the significant variability in measurements of LV diastolic function by MUGA limits its clinical application.(205)”
Expert consensus for multimodality imaging evaluation of adult patients during and after cancer therapy: a report from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. (2014, background): “As mentioned with echocardiography, the significant variability in measurements of LV diastolic function by MUGA limits its clinical application.(205)”
Cardiotoxicity of anthracycline agents for the treatment of cancer: Systematic review and meta-analysis of randomised controlled trials (2010, methodology): “A large observational study of cardiac complication rates of women aged 66 to 80 years old receiving adjuvant anthracyclines using the Surveillance, Epidemiology and End Results (SEER) database has been conducted [80].”
2016 ESC Position Paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC Committee for Practice Guidelines: The Task Force for cancer treatments and cardiovascular toxicity of the European Society of Cardiology (ESC). (2016, background): “10 years of follow-up.(96) However, there was no such increase in risk of congestive HF in the long-term follow-up of patients treated with adjuvant anthracyclines followed by trastuzumab.”
2016 ESC Position Paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC Committee for Practice Guidelines (2016, background): “10 years of follow-up.(96) However, there was no such increase in risk of congestive HF in the long-term follow-up of patients treated with adjuvant anthracyclines followed by trastuzumab.”